Ontology highlight
ABSTRACT:
SUBMITTER: Furman RR
PROVIDER: S-EPMC4161365 | biostudies-literature | 2014 Mar
REPOSITORIES: biostudies-literature
Furman Richard R RR Sharman Jeff P JP Coutre Steven E SE Cheson Bruce D BD Pagel John M JM Hillmen Peter P Barrientos Jacqueline C JC Zelenetz Andrew D AD Kipps Thomas J TJ Flinn Ian I Ghia Paolo P Eradat Herbert H Ervin Thomas T Lamanna Nicole N Coiffier Bertrand B Pettitt Andrew R AR Ma Shuo S Stilgenbauer Stephan S Cramer Paula P Aiello Maria M Johnson Dave M DM Miller Langdon L LL Li Daniel D Jahn Thomas M TM Dansey Roger D RD Hallek Michael M O'Brien Susan M SM
The New England journal of medicine 20140122 11
<h4>Background</h4>Patients with relapsed chronic lymphocytic leukemia (CLL) who have clinically significant coexisting medical conditions are less able to undergo standard chemotherapy. Effective therapies with acceptable side-effect profiles are needed for this patient population.<h4>Methods</h4>In this multicenter, randomized, double-blind, placebo-controlled, phase 3 study, we assessed the efficacy and safety of idelalisib, an oral inhibitor of the delta isoform of phosphatidylinositol 3-kin ...[more]